In tablet manufacture for pre-ruminant calves, the liquid extract is sprayed onto a 1:1 carrier mixture of microcrystalline cellulose and colloidal silicon dioxide inside a top-spray fluid-bed granulator. The two-fluid nozzle is specified at 0.8 mm orifice diameter with atomizing air pressure between 2.0 bar and 2.5 bar; inlet air temperature is commonly limited to 45–50°C for heat-sensitive botanical extracts because higher temperatures are associated with surface darkening and reduced recovery of aromatic marker compounds. The bed temperature is maintained at 42±3°C, and the adsorption end point is determined by loss-on-drying with final blend moisture held below 3.5% before compression. The dried adsorbate is screened through an 800 µm sieve and blended with crospovidone at 2 wt%, colloidal silicon dioxide at 0.5 wt%, and sodium stearyl fumarate at 1.2 wt% in a bin blender for 3 minutes at 6 rpm. Compression is performed on a 27-station rotary tablet press with 10 mm round flat-faced tooling. Hardness is set between 6 kp and 9 kp, friability below 0.8% after 100 revolutions, and disintegration not more than 15 minutes in 900 mL water at 37±2°C. Content uniformity must comply with USP <905>; dissolution profiling is conducted according to USP <711>. If the tablet is film-coated, the aqueous coating step introduces a second moisture load: the uncoated core is heated to 40°C, the coating suspension is applied at 4–6 g/min per kg tablet charge, and exhaust humidity must remain below 20% RH. A seal coat is mandatory when the formulation contains a highly hygroscopic disintegrant because edge chipping and core expansion increase when the seal coat is omitted.

What limits sterile filtration throughput when the liquid API is converted to a parenteral dosage form?

Parenteral use of Huoxiang Perfusion Solution Veterinary Grade API is constrained by particle load, endotoxin burden, and pH shift after dilution with water for injection. The concentrated extract is diluted to a target solids content below 2.0% w/v; above this level, the 0.22 µm polyvinylidene fluoride sterilizing-grade membrane loses flux quickly on production-scale cartridge housings. A serial filtration train of a 0.8 µm glass-fibre prefilter, a 0.45 µm polyethersulfone prefilter, and a 0.22 µm sterilizing-grade filter is installed. If the diluted solution is not clarified first by centrifugation at 10,000 × g for 10 minutes, the glass-fibre prefilter becomes loaded after less than 5 L per 0.09 m² of membrane area in pilot-scale runs. Aseptic filling is required because terminal steam sterilization is not assumed for this botanical extract unless thermal stability data are available; the operation follows EU GMP Annex 1, and sterility testing must comply with Ph. Eur. 2.6.1. Particulate matter in the filled solution must meet USP <788> for large-volume parenterals: not more than 25 particles/mL at ≥10 µm and not more than 3 particles/mL at ≥25 µm. Bacterial endotoxin limits are derived from the intended maximum dose and species body weight; test methodology follows USP <85> or Ph. Eur. 2.6.14. The pH is adjusted with dilute hydrochloric acid or sodium hydroxide to 5.0–6.5; precipitation is a known risk below pH 4.2 and above pH 7.8 for polyphenol-rich botanical extracts. Because the extract contains polyphenolic compounds, the solution is filled under low-oxygen headspace to suppress browning. The drug product should not be held in stainless steel lines for prolonged periods without passivation verification, because iron-chelating constituents may discolour the batch.

Premix production for medicated feed uses calcium carbonate as the first-stage carrier because its particle surface area and low affinity for polyphenolic pigments allow better batch-to-batch colour consistency than rice hulls. The liquid extract is charged at 8 wt% onto calcium carbonate in a ploughshare mixer with chopper at 1,500 rpm for 3 minutes. The wet intermediate is transferred to a fluid-bed dryer at 45°C and dried to residual moisture below 2.5%. This primary premix is then diluted 1:10 with ground corn or rice hulls in a horizontal ribbon blender at 40 rpm for 10 minutes. Homogeneity is assessed by thief sampling at 10 locations following ISO 6497:2002; the relative standard deviation of the marker content must remain below 5% for release. The process is considered homogeneous only when the analytical method meets Ph. Eur. 2.2.29 for liquid chromatography. Carryover is a production bottleneck: the next batch must be protected by a cleaning protocol using 0.5% sodium hydroxide solution at 60°C followed by potable water at 80°C; analytical verification is required because visual cleanliness does not detect polyphenolic residues. Bentonite binders should not be introduced into the same premix without compatibility testing, because phyllosilicate lamellae can adsorb the extract's aromatic components and reduce recovered marker content. In-process sampling and testing follow 21 CFR 211.110, and veterinary premix manufacture is subject to EU Regulation 2019/6 where applicable.

When hard capsule shells act as secondary containers rather than dry-fill matrices

For companion animal capsules, the liquid extract can be filled directly into hard capsules only when the shell is selected as a moisture barrier, not as a dry-fill matrix. The fill pump is set to maintain the liquid at 35–40°C; at ambient temperature the viscosity exceeds the volumetric pump's tolerance and causes capsule weight variation. Gelatin capsules are not recommended when the fill water activity is above 0.45 because the shell plasticizes and deforms in the filling line. Hydroxypropyl methylcellulose capsules are preferred for this route. After filling, the capsule is band-sealed with an aqueous hydroxypropyl methylcellulose solution at 3–5% w/v and 50–60°C. Leakage testing is performed at -50 kPa for 10 minutes with no visible leakage. Weight variation must comply with Ph. Eur. 2.9.5, and dissolution testing follows USP <711> with a suitable aqueous medium. The filled shells are brittle below 20% RH and soften above 60% RH; therefore blister cavities are specified with aluminium foil backing and a desiccant pouch. The direct liquid fill route is operationally limited to small batch sizes because the band-sealing step creates a bottleneck when more than 50,000 capsules per shift are processed on a single lane. Published data for this specific extract in hard capsule stability at accelerated storage are limited; therefore a bracketed stability protocol must be used before commercial release.

For reconstitutable oral powders, the liquid API is converted to a spray-dried composite rather than a simple physical blend. The feed solution is prepared by mixing the extract with maltodextrin of dextrose equivalent 10–15 and colloidal silicon dioxide at 0.5 wt%. Spray drying is operated with an inlet temperature of 160–180°C and an outlet temperature of 80–90°C; these conditions are standard for botanical extract carriers, but published data for this specific perfusion solution under high-temperature spray drying are limited, so marker degradation must be tracked by liquid chromatography for each lot. The resulting powder is milled, blended, and passed through a 250 µm mesh. Water activity is maintained below 0.35 using desiccant-loaded packaging, and moisture uptake is monitored by USP <1112> or equivalent loss-on-drying. The reconstitution behaviour is tested in hard water equivalent to 500 ppm calcium carbonate; a precipitate after 5 minutes is a release failure. If precipitation occurs, citric acid at 0.2% w/v may be added only after a compatibility study demonstrates no degradation of marker compounds over the intended storage period. High-shear blending should be avoided because the powder contains a fine silica component that segregates during prolonged mixing; bin blending at 6 rpm for 5 minutes is sufficient for uniformity. The powder must be packaged in moisture-proof foil pouches; bulk storage in polyethylene-lined drums is not recommended above 25°C.

Granule geometry and drying kinetics during low-shear wet granulation for piglet oral delivery

Low-shear wet granulation of the adsorbed extract is used when the final oral granule must retain porosity for rapid dispersion in piglet feeding systems. The dry pre-mix is wetted with a 5% w/v povidone K30 solution at 8% of the dry mass in a planetary mixer at 60 rpm. The wet mass is extruded through a 0.8 mm screen and spheronized at 400 rpm for 5 minutes. The granules are dried in a fluid-bed dryer at 50°C until residual moisture is below 3%; the target granule fraction is 700–1000 µm. Over-wetting is the principal field failure: when the binder solution exceeds 10% of the dry mass, the extruder screen clogs and the chopper motor current increases by more than 20% on pilot-scale batches. Flowability is assessed by angle of repose, which must remain below 40° for automated sachet filling; the method follows Ph. Eur. 2.9.36. The dissolution profile of the finished granules is not assumed to match the tablet profile because granule porosity and carrier hydrophilicity control wetting. The granules may be filled into sachets or used as a top dressing, but direct addition to milk replacer is restricted to formulations that have been tested for clumping at 35–38°C liquid temperature.

Chlorinated drinking water destabilises polyphenolic markers within two hours unless the dosing line is buffered

When the liquid API is injected into drinking water through a calibrated proportioner pump, water matrix chemistry is the main release risk. The stock solution should be prepared daily because microbial proliferation in diluted standing solution is observed after 24 hours at ambient temperature. The target dilution water pH is 5.5–7.5; below pH 4.0 visible precipitation occurs, and above pH 8.5 alkaline hydrolysis of polyphenolic markers accelerates. Municipal chlorinated water with residual free chlorine from 0.5 ppm to 4 ppm may oxidise the extract, so the API must be introduced downstream of any chlorine contact tank and must not be pre-mixed in header tanks that retain chlorine-based disinfectants. Elevated water hardness does not generally cause immediate precipitation, but copper and galvanized iron fittings in the distribution line are a known source of colour change because polyphenolic constituents chelate Cu²⁺ and Fe²⁺; contact with these materials should not exceed 2 hours. Co-administration with tetracycline hydrochloride or other cationic drugs in the same water line is not recommended without a jar test, because both compounds may compete for complexation. The proportioner pump calibration must be verified daily, and the final water solution must be inspected for visible particles at 2 hours; any turbidity indicates incompatibility with water chemistry or line material. Analytical monitoring of diluted solution may be performed by liquid chromatography; published data for this specific extract under hypochlorite challenge are limited.